AmpliPhi Biosciences

AmpliPhi Biosciences is focused on developing novel bacteriophage-based therapeutics.

Business Model:

Revenue: $0

Employees: 11-50

Detailed AmpliPhi Biosciences Information

Geographic Data

AmpliPhi Biosciences headquarters map

Address:

City: Richmond

State: Virginia

Zip:

Country: United States

Financial Info

Stage:

post ipo equity

Raised Last:

$13M

Raised Total:

$44M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections. AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.

Contact Phone:

Contact Email:

AmpliPhi Biosciences went public on 5/12/2006 on the NYSE

Listed Exchange:
NYSE

IPO Date:
5/12/2006

Ticker Symbol:
APHB

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
12/2013 Post-IPO Equity 1 $18M ROTH Capital Partners
ROTH Capital Partners
7/2013 Post-IPO Equity $0 RA Capital Management
BioScience Managers Limited
Third Security
RA Capital Management
BioScience Managers Limited
Third Security
2/2013 Post-IPO Debt $500k
1/2004 Venture Round 1 - Venrock
Venrock
3/2015 Post-IPO Equity $13M
7/2013 Post-IPO Equity 3 $12.5M RA Capital Management
BioScience Managers Limited
Third Security
RA Capital Management
BioScience Managers Limited
Third Security
1/2004 Venture Round 1 - Venrock
Venrock
Announced Date Name Price
1/2019 C3J Therapeutics
1/2016 Novolytics
1/2011 Biocontrol

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research